In this video, Motley Fool analysts and editors David Williamson and Andrew Tonner sit down and catch up on how the week treated health-care stocks.
In this edition, four biotech companies dominated the news. There was a positive FDA panel vote, but most of it centered around three critical trial results -- results that can be best described using the famed "the good, the bad, and the ugly" moniker. We highlight key takeaways from each event and lend our opinion on what investors should be looking at going forward.
To see which biotechs soared and which stocks cratered, click on the video below.
David Williamson and Andrew Tonner own no shares in any company mentioned. Click here to see David Williamson's holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.